Table 4 Risk factors associated with development of breakthrough BSI during tigecycline therapy.
Variable | Univariate analysis | Multivariable analysis1 | ||
---|---|---|---|---|
Odds ratio (95% CI) | P value | Odds ratio (95% CI) | P value | |
Liver cirrhosis | 4.51 (1.96–10.37) | < 0.001 | 3.09 (1.13–8.46) | 0.028 |
Solid organ transplantation | 2.94 (1.30–6.68) | 0.01 | ||
Charlson comorbidity score | 1.13 (1.01–1.27) | 0.043 | ||
Indwelling catheter2 | 2.76 (1.29–5.90) | 0.009 | 3.42 (1.38–8.48) | 0.008 |
Previous Candida colonization | 7.39 (2.12–25.73) | 0.002 | 14.95 (3.58–62.49) | < 0.001 |
Previous multidrug-resistant pathogen colonization3 | 9.85 (5.27–18.40) | < 0.001 | 10.30 (5.20–20.43) | < 0.001 |
APACHE II score | 1.08 (1.04–1.12) | < 0.001 |